Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
TA918: Bimekizumab for treating axial spondyloarthritis
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA718: Ixekizumab for treating axial spondyloarthritis
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
16/12/2020
TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
25/11/2020
TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
25/11/2020
TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
18/11/2020
TA656: Siponimod for treating secondary progressive multiple sclerosis
18/11/2020
TA657: Carfilzomib for previously treated multiple myeloma
18/11/2020
TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
18/11/2020
TA659: Galcanezumab for preventing migraine
21/10/2020
TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
20/10/2020
TA457: Carfilzomib for previously treated multiple myeloma
Evidence-based recommendations
on carfilzomib (Kyprolis) for treating multiple myeloma in adults.
14/10/2020
TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
14/10/2020
TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
12/10/2020
TA604: Idelalisib for treating refractory follicular lymphoma
12/10/2020
TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
12/10/2020
TA631: Fremanezumab for preventing migraine
12/10/2020
TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
12/10/2020
TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
12/10/2020
TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
12/10/2020
TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
12/10/2020
TA649:Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
01/10/2020
TA651: Naldemedine for treating opioid-induced constipation
1
2
3
4
5
6
7
8
9
10
11
Follow AWTTC: